Validation of the Vitiligo Noticeability Scale: a patient-reported outcome measure of Vitiligo treatment success by Batchelor, J.M. et al.
GENERAL DERMATOLOGY
BJD
British Journal of Dermatology
Validation of the Vitiligo Noticeability Scale: a patient-
reported outcome measure of vitiligo treatment success*
J.M. Batchelor,1 W. Tan,2 S. Tour,1 A. Yong,3 A.A. Montgomery2 and K.S. Thomas1
1Centre of Evidence Based Dermatology, King’s Meadow Campus, Lenton Lane, Nottingham NG7 2NR, U.K.
2Nottingham Clinical Trials Unit, Queen’s Medical Centre, C Floor, South Block, Nottingham NG7 2UH, U.K.
3Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich NR4 7UY, U.K.
Correspondence
Jonathan M. Batchelor.
E-mail: jonathan.batchelor@nottingham.ac.uk
Accepted for publication
23 September 2015
Funding sources
This project was funded by the National Institute
for Health Research (NIHR) Health Technology
Assessment Programme (project number 12/24/
02). The views and opinions expressed herein are
those of the authors and do not necessarily reflect
those of the Health Technology Assessment pro-
gramme, NIHR, National Health Service or the
Department of Health.
Conflicts of interest
None declared.
*Plain language summary available online
DOI 10.1111/bjd.14208
Summary
Background Patient-reported outcome measures are rarely used in vitiligo trials.
The Vitiligo Noticeability Scale (VNS) is a new patient-reported outcome measure
assessing how ‘noticeable’ vitiligo patches are after treatment. The noticeability
of vitiligo after treatment is an important indicator of treatment success from the
patient’s perspective.
Objectives To evaluate the construct validity, acceptability and interpretability of
the VNS.
Methods Clinicians (n = 33) and patients with vitiligo (n = 101) examined 39
image pairs, each depicting a vitiligo lesion pre- and post-treatment. Using an
online questionnaire, respondents gave a global assessment of treatment success
and a VNS score for treatment response. Clinicians also estimated percentage
repigmentation of lesions (< 25%; 25–50%; 51–75%; > 75%). Treatment success
was defined as ‘yes’ on global assessment, a VNS score of 4 or 5, and > 75%
repigmentation. Agreement between respondents and the different scales was
assessed using kappa (j) statistics.
Results Vitiligo Noticeability Scale scores were associated with both patient- and
clinician-reported global treatment success (j = 054 and j = 047, respec-
tively). Percentage repigmentation showed a weaker association with patient- and
clinician-reported global treatment success (j = 039 and j = 029, respec-
tively). VNS scores of 4 or 5 can be interpreted as representing treatment success.
Images depicting post-treatment hyperpigmentation were less likely to be rated
as successful.
Conclusions The VNS is a valid patient-reported measure of vitiligo treatment suc-
cess. Further validation of the VNS is required, using larger sets of clinical pre-
and post-treatment images, affecting a wider range of anatomical sites.
What’s already known about this topic?
• The lack of standardized outcome measures makes comparison of vitiligo treatment
efficacy difficult.
• Patient-reported outcome measures are rarely used in vitiligo trials.
• Patient-reported outcome measures assessing vitiligo treatment success from the
patient’s perspective have yet to be developed.
• The Vitiligo Noticeability Scale (VNS) is a new patient-reported outcome measure
of treatment response, which has been shown to have face validity.
What does this study add?
• The VNS has good construct validity, acceptability and interpretability, supporting
its inclusion as a patient-reported measure of the cosmetic acceptability of treat-
ment response in vitiligo trials.
© 2015 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
386 British Journal of Dermatology (2016) 174, pp386–394
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
• The VNS is a better and more consistent indicator of global treatment success than
percentage repigmentation.
• VNS scores of 4 or 5 can be interpreted as representing treatment success.
• Further validation of the VNS is required.
Vitiligo is a chronic depigmenting disease, with a prevalence
of 05–10%. Various treatments have been evaluated, includ-
ing topical and oral preparations, light therapy, surgical proce-
dures, psychological and complementary therapies.1,2
Despite the large number of randomized controlled trials
(RCTs) assessing vitiligo treatments, the lack of standardized
outcome measures makes comparison of treatment efficacies
difficult.2–5 A systematic review reported 25 different outcome
measures across 54 trials.4 Patient-rated outcomes such as cos-
metic acceptability were assessed in just nine of 54 (17%) of
the trials. Although percentage repigmentation was reported in
96% of trials (usually with ≥ 75% repigmentation represent-
ing treatment success), it was measured in 48 different ways,
making comparison impossible.4 Moreover, there have been
no attempts to validate the use of ≥ 75% repigmentation,
assessed by a clinician, to represent treatment success. To
enable treatment comparison, work has been done to identify
a set of core outcome measures that can be used in RCTs.
International consensus has been reached for seven outcome
domains, including repigmentation and cosmetic acceptability
of treatment response.6
Inclusion of patient-rated outcome measures in RCTs of
vitiligo treatments has been recommended,2,4,5 but validated
measurement scales are limited. Scales to assess psychosocial
impact and quality of life in patients with vitiligo have
recently been validated.7–9 These scales include some elements
that relate to the appearance of the vitiligo, but they cannot
be used specifically to assess the appearance of the vitiligo
after treatment or perceived ‘treatment success’ from the
patient’s perspective.
The Vitiligo Noticeability Scale (VNS) is a patient-rated out-
come measure of vitiligo treatment response. We previously
developed this scale through a process using consensus
methodology, involving 165 patients.10 This involved an
online survey, to identify which aspects of treatment response
are most important to patients, and online discussion groups,
to explore the survey results with patients, and reach consen-
sus regarding the wording for a proposed patient-reported
outcome measure. The phrase ‘cosmetically acceptable
response’ was not meaningful to people with vitiligo, as it
seemed vague and impersonal. In contrast, they thought that
‘how noticeable’ the vitiligo is, the ‘colour match’ between
their vitiligo and normal skin and a ‘reduction in the size of
the vitiligo patches’ were more meaningful measures of treat-
ment response. The participants reached consensus that the
‘noticeability’ of the vitiligo was the most important of these
concepts for assessing the success of treatment response; a
scale with five response options (both words and numbers)
would be the best scale to use when assessing treatment
response (whereas giving a binary ‘yes’/’no’ response was
more difficult); and a score of 4 or 5 on the scale would rep-
resent a successful treatment response.8 Table 1 shows the
details of the VNS.
This article reports on work to further validate the VNS.
The main hypothesis was that the VNS would be a better and
more consistent indicator of treatment success than percentage
repigmentation.
In relation to this main hypothesis, we aimed to answer the
following questions: ‘What is the construct validity of the
VNS (compared with global treatment success as reference
standard), and how does VNS compare with clinician-rated
percentage repigmentation?’. Construct validity is defined as
the degree to which scores of a given measurement instru-
ment are consistent with hypotheses relating to the relation-
ship between that measurement instrument and other relevant
scales.11 Construct validity is established by testing specific
hypotheses.
In relation to the VNS we hypothesized that (i) there would
be a positive association between VNS and global treatment
success, with a kappa (j) statistic of ≥ 04; (ii) the VNS
would have better association with global treatment success
than with percentage repigmentation; and (iii) clinician- and
Table 1 Questions used to assess pre- and post-treatment images
Question
Response options
(score)
Success
criteria
VNS
Compared with
before treatment,
how noticeable is
the vitiligo now?
More noticeable (1)
As noticeable (2)
Slightly less noticeable (3)
A lot less noticeable (4)
No longer noticeable (5)
Score of
4 or 5
Global treatment success
Do you think this
treatment was
successful?
If ‘no’ please state
why
Yes
No
Yes
Percentage repigmentation
Please state the level
of repigmentation
you think has been
achieved in the
‘after treatment’
image
< 25%
25–50%
51–75%
> 75%
> 75%
VNS, Vitiligo Noticeability Scale.
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patient-assessed VNS scores would show agreement, with
j ≥ 04.
The second question was as follows: ‘What is the accept-
ability and interpretability of the VNS?’. The acceptability of a
measurement instrument refers to whether or not an individ-
ual is willing to give a response to it, and how easy it is for
them to do so.11 The present study included an assessment of
how easy the VNS is to use.
The interpretability of a measurement instrument refers to ‘the
degree to which one can assign qualitative meaning – that is,
clinical or commonly understood connotations – to an instru-
ment’s quantitative scores or change in scores’.11 A score of ≥ 4
on the five-point VNS had previously been proposed to repre-
sent treatment success.10 The present study sought to further
investigate this proposed cut-off, comparing it with global treat-
ment success, in order to assess interpretability of the VNS.
The third question was: ‘What factors influence VNS
scores?’. We sought to explore factors that may influence the
VNS scores. These included characteristics of the vitiligo
patches, characteristics of the patients and characteristics of the
clinicians.
Materials and methods
This validation study was performed using an online question-
naire, completed by people with vitiligo and clinicians (der-
matologists). Approval for the study was granted by the
University of Nottingham’s research ethics committee (Ref.
LTg15082013 SoM Dermatol).
Participants and setting
People with vitiligo (n = 188) on a mailing list held at the
Centre of Evidence Based Dermatology (CEBD), University of
Nottingham, received an email invitation to participate. The
list included participants from a Vitiligo Priority Setting Part-
nership,3 or those who had expressed interest in being
involved in vitiligo research. Participants were also recruited
through the Facebook page of the U.K. Vitiligo Society, and
the survey’s web link was tweeted through the U.K. Dermatol-
ogy Clinical Trials Network Twitter account (http://
www.ukdctn.org).12 The clinician questionnaire was sent to
U.K.-based dermatologists who had previously expressed an
interest in recruiting patients for a vitiligo RCT (n = 21), and
dermatologists involved in the international initiative to
develop core outcomes for vitiligo (n = 51).
Pre- and post-treatment digital images
We created a bank of images showing vitiligo lesions pre- and
post-treatment.
We sourced 10 pretreatment images of vitiligo from (i) a
database held at the CEBD (with written consent from
patients); (ii) published papers (after obtaining relevant per-
missions); and (iii) images in the public domain. We chose
images showing vitiligo on the face (n = 27) and hands
(n = 12) as ‘high-expression sites’, where vitiligo is more visi-
ble. To ensure broad demographic coverage, we selected
images showing both sexes (male, n = 14; female, n = 14;
neutral, n = 11) with a range of skin phototypes (Table S1;
see Supporting Information).
For four of the ‘pretreatment’ images, a suitable paired
‘post-treatment’ image was available, showing the same patch
of vitiligo after treatment. We created other image pairs via
image manipulation: the pretreatment image was copied and
digitally altered using Adobe Photoshop CS6 Extended (pre-
dominantly clone stamp, healing brush, spot healing and
patch tools; Adobe, San Jose, CA, U.S.A.) to simulate varying
degrees of skin repigmentation, in a ‘post-treatment’ image.
In total, we created 35 image pairs, using the same pretreat-
ment images to create sets of post-treatment images. We cre-
ated more images to show approximately 70–80%
repigmentation (determined by the clinician authors), as clini-
cian-assessed repigmentation of ≥ 75% is often taken to repre-
sent treatment success.4 The ‘post-treatment’ images showed
common patterns of repigmentation – perifollicular (n = 13),
marginal (n = 13) and diffuse (n = 11) – with some images
also showing hyperpigmentation (n = 6).13 We created a total
of 39 ‘post-treatment’ images.
Data collection
We created a questionnaire using the online survey tool Sur-
vey Monkey (http://www.surveymonkey.com). We made one
version of the questionnaire for people with vitiligo and
another for clinicians. We asked three people with vitiligo and
three clinicians to pilot test the questionnaires.
We sent potential patient participants an explanatory email,
with a web link to the questionnaire. We sent email reminders
on three occasions and placed repeated posts on the Vitiligo
Society Facebook page. To encourage participation, we
pledged a £10 donation to the Vitiligo Society for every com-
pleted questionnaire received.
The questionnaire included questions about the respon-
dents’ vitiligo (if applicable) and basic demographic character-
istics, followed by the 39 pairs of pre- and post-treatment
images, with each pair presented on a new screen. Respon-
dents were asked to assess each image pair using the two
questions shown in Table 2. Examples of ‘pre- and post-’
image pairs are shown in Figure 1. (Note: both of the post-
treatment images are simulated images.) Clinicians were addi-
tionally asked to rate percentage repigmentation in the post-
treatment image (< 25%, 25–50%, 51–75%, > 75%).
Image pairs were presented in a random sequence and
respondents were permitted to navigate only forwards through
the questionnaire; they could not edit previous responses.
To assess the acceptability of the VNS, after assessing all of
the 39 image pairs, respondents were asked the question,
‘How easy was it for you to judge the answers to the ques-
tions given for each set of images?’ (using a five-point scale:
very easy, easy, okay, difficult, very difficult). Respondents
could also add their own comments.
© 2015 The Authors. British Journal of Dermatology
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Sample size
As all three of our hypotheses about the VNS were based on
estimating and comparing j statistics, we aimed to have suffi-
cient precision for these statistics [defined as half of the width
of the 95% confidence interval (CI) of j]. We investigated the
association between sample size and the precision of the j
estimate using simulations. We created multiple simulated data
sets of varying size, in which each observation consisted of 39
binary ratings of treatment success or failure. To simulate our
survey, these 39 scores were clustered as 13 sets of three. By
varying the intracluster correlation coefficient for treatment
response at this level, and at observation level, and the overall
proportion of successes, we found that for sample sizes > 100
the precision of j reached a plateau. Therefore, we aimed to
include at least 100 patient respondents in the survey.
Statistical analyses
We performed all analyses with STATA version 13 (Stata
Corp., College Station, TX, U.S.A.). We included all available
data in the analyses and did not impute any missing data.
There is no gold standard for assessment of treatment suc-
cess in patients with vitiligo, so as a reference standard we
used patient- and clinician-reported treatment success on a
‘yes/no’ binary scale (see Table 1). We estimated crude agree-
ment between the scales and the reference standard by con-
verting the five-point VNS and the four-point percentage
repigmentation scales into binary measures of success (suc-
cess = VNS scores ≥ 4; percentage repigmentation > 75%).
We assessed the extent of agreement between these binary
scales using j statistics (two outcomes, more than one rater)
separately for patients and clinicians, with bootstrapping to
estimate 95% CIs,13 and allowing for clustering at both the
level of the respondent and image ‘set’ defined by the 10 pre-
treatment images. We used the repigmentation category cho-
sen by the majority of the clinicians to assign each image to
the relevant percentage repigmentation category.
We estimated agreement between patients and clinicians on
the VNS by calculating separate j values for all possible
patient–clinician pairs and taking the mean, with the 95% CI
estimated by bootstrapping.14 The Consensus-based Standards
for the Selection of Health Measurement Instruments (COS-
MIN) checklist states that for a scale to be acceptable, correla-
tions between two instruments measuring the same construct
should be j ≥ 050, or 75% of the results should be in accor-
dance with a priori hypotheses.15 However, in this study we
took a j ≥ 04 to show an acceptable (moderate) level of
agreement with global treatment success, as this unvalidated
scale may assess a slightly different but related construct.
Factors influencing VNS scores were explored using multi-
variable logistic regression. Characteristics of the vitiligo
patches included in the logistic regression model were
anatomical location of the lesion, pattern of repigmentation,
sex of the person in the image, level of repigmentation, and
presence or absence of hyperpigmentation. We included
patients’ characteristics in the patient-rated VNS treatment suc-
cess model and clinicians’ characteristics in the clinician-rated
VNS treatment success model. Characteristics of the respon-
dents included in the logistic regression model were age, sex,
ethnicity, country of residence, level of expertise (clinician
respondents only), and extent and duration of the vitiligo (pa-
tient respondents only).
Results
The online questionnaire was open from December 2013 to
March 2014. There were 101 complete responses to the
patient questionnaire; eight were from proxy respondents. The
Table 2 Demographic and clinical characteristics of respondents
Patient respondents
(n = 101)
Clinician respondents
(n = 33)
Sex
Male 35 (35) 17 (52)
Female 65 (64) 16 (48)
NS 1 (1) 0
Age (years)a
< 16 10 (10) 0
17–30 14 (14) 1 (3)
31–45 24 (24) 11 (33)
46–65 36 (36) 19 (58)
> 65 15 (15) 1 (3)
NS 2 (1) 1 (3)
Duration of vitiligo
6–12 months 1 (1) –
1–2 years 5 (5) –
2–5 years 11 (11) –
5–10 years 13 (13) –
> 10 years 71 (70) –
Approximate percentage of skin affected
< 10 24 (24) –
10–25 38 (24) –
25–50 17 (16) –
50–80 15 (15) –
> 80 7 (7) –
Ethnicity
White British 70 (69) 6 (18)
Other white 11 (11) 10 (30)
Asian/mixed 11 (11) 4 (12)
Black/mixed 5 (5) 3 (9)
Other 3 (3) 9 (27)
NS 1 (1) 1 (3)
Country of residence
U.K. 79 (78) 14 (42)
Australia 4 (4) 0
Canada 2 (2) 0
Egypt 3 (3) 7 (21)
U.S.A. 5 (5) 2 (6)
Otherb 8 (8) 10 (30)
Data are n (%). NS, not stated. aEight respondents answered the
survey on someone else’s behalf. bOther countries included Bra-
zil, China, Costa Rica, France, Greece, Ireland, Japan, Latvia,
Malaysia and Norway.
© 2015 The Authors. British Journal of Dermatology
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clinician questionnaire was completed by 33 dermatologists,
18 (54%) of whom had a special interest in vitiligo. The char-
acteristics of the respondents are shown in Table 2. While the
majority of respondents were from the U.K., patients and clin-
icians from 15 other countries also took part. A small number
of questions within the survey did not receive responses. For
the 101 respondents to the patient questionnaire, 3613 out of
a possible 3939 (92%) responses to the VNS and global suc-
cess ratings were received. For the 33 clinicians, 1217 out of
a possible 1287 responses (94%) were received for the three
scales.
Question 1: ‘What is the construct validity of the Vitiligo
Noticeability Scale (compared with global treatment
success as reference standard), and how does the
Vitiligo Noticeability Scale compare with clinician-rated
percentage repigmentation?’
We compared scores on the VNS and percentage repigmenta-
tion scale with global treatment success. Crude agreement in
classifying treatment response using the VNS compared with
global treatment success scale was 78% and 76% for patients
and clinicians, respectively. Crude agreement in classifying
treatment response using percentage repigmentation compared
with global treatment success was 62% for clinicians
(Table 3).
The VNS showed good-to-moderate agreement with
patient- and clinician-reported global treatment success
(j = 054 and j = 047, respectively). This supports our first
hypothesis – that there would be a positive association
between VNS and global treatment success, with j ≥ 04.
In contrast, percentage repigmentation showed only fair
agreement with patient- and clinician-reported global treat-
ment success (j = 039 and j = 029, respectively). This,
together with the better levels of agreement between the VNS
and global treatment success, supports the second hypothesis
– that the VNS would have better association with global treat-
ment success than percentage repigmentation.
Comparing patient- and clinician-rated VNS scores showed
a moderate-to-good association (j = 043). This supports our
third hypothesis that clinician- and patient-assessed VNS scores
would show agreement, with a j ≥ 04.
Question 2: ‘What is the acceptability and
interpretability of the Vitiligo Noticeability Scale?’
The majority of patients (57%) reported that the VNS was
‘very easy’ or ‘easy’ to complete, and 36% reported that it
was ‘okay’. Only 7% said it was ‘difficult’ to complete and
none said it was ‘very difficult’. These results suggest that the
VNS is an acceptable and intuitive scale for completion by
patients.
While the five-point VNS may be reported descriptively for
all levels, the proposed cut-off for a successful treatment
response was a score of ≥ 4 points.10 The current study sup-
ported this classification: 94% and 99% of the images were
(a)
(b)
Fig 1. Examples of pre- and post-treatment
image pairs (note: post-treatment images are
simulated). (a) Female face, type V/VI skin,
marginal repigmentation (approximately
50%). (b) Male face, type I/II skin,
perifollicular repigmentation (approximately
70%) with hyperpigmentation.
© 2015 The Authors. British Journal of Dermatology
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classed as a treatment success for VNS scores of 4 and 5,
respectively, and 95% and 87% of the images classed as
unsuccessful for VNS scores of 1 and 2, respectively (Table 3).
Nevertheless, a score of 3 on the VNS scale was considered to
be a successful treatment for 65% of the image pairs, suggest-
ing that a VNS score of 3 may represent treatment success for
some patients.
Question 3: ‘What factors influence Vitiligo Noticeability
Scale scores?’
For patient respondents, the percentage and pattern of repig-
mentation, and presence of hyperpigmentation, were all asso-
ciated with rating the treatment as successful (Table 4). The
age and country of residence of patient respondents, and the
age of clinician respondents, were also associated with rating
the treatment as successful (Table 4).
The number of clinician respondents was relatively small
and, compared with nondermatologists, all were likely to have
some expertise in treating vitiligo, so the division between
‘experts’ and ‘nonexperts’ in this study is less clear than it
would be between ‘dermatologists’ and ‘nondermatologists’.
Therefore, although we found no clear evidence in this study
that the level of vitiligo expertise had any association with rat-
ing treatment as successful, it is not possible to draw firm
conclusions from this dataset.
Discussion
Until now there have been no validated scales allowing people
with vitiligo to rate treatment response. This study suggests
that the patient-reported VNS has good construct validity,
acceptability and interpretability, supporting its inclusion as a
patient-reported measure of the cosmetic acceptability of treat-
ment response in vitiligo RCTs.
Patients with vitiligo were central to the development of
the VNS,10 and so it is perhaps unsurprising that VNS scores
correspond well with patients’ views of what constitutes treat-
ment success. This study would suggest that a VNS score of 4
or 5 (i.e. ‘a lot less noticeable’ or ‘no longer noticeable’)
should be interpreted as ‘successful treatment response’; a
VNS score of 3 as ‘partially successful’; and a VNS score of 1
or 2 as ‘unsuccessful’. This may be a better representation of
the entire clinical picture than a binary division of scores into
‘successful’ (VNS score 4 or 5) and ‘unsuccessful’ (VNS score
1, 2 or 3).
The results shown here support our a priori hypotheses
regarding the level of agreement expected for the different
comparisons. This supports our main hypothesis that the VNS
is a better and more consistent indicator of global treatment
success than percentage repigmentation. Agreement was better
between the patient-reported scales than between the clini-
cian-reported scales, lending support to the use of VNS as a
patient-rated measure.
The observation that hyperpigmentation of vitiligo patches
has an adverse effect on patient-reported treatment success
may explain the lower level of agreement between percentage
repigmentation and treatment success. Percentage repigmenta-
tion measures the amount of repigmentation, regardless of the
visual appearance of the skin, and so may overestimate treat-
ment ‘success’. Similarly, in cases where repigmentation is dif-
fuse, there may be some restoration of pigment across the
entire patch, which could be interpreted as ‘100% repigmen-
tation’; however, the overall colour of the patch may still be
Table 3 Comparison of global treatment success vs. the Vitiligo Noticeability Scale (VNS) and percentage repigmentation
Patients (n = 101) Clinicians (n = 33)
Treatment success Treatment success
No Yes No Yes
VNS scorea
1 = more noticeable 103 (95) 5 (5) 31 (84) 6 (16)
2 = as noticeable 532 (87) 81 (13) 110 (73) 42 (27)
3 = slightly less noticeable 342 (35) 624 (65) 109 (35) 204 (65)
4 = a lot less noticeable 92 (6) 1552 (94) 37 (6) 594 (94)
5 = no longer noticeable 2 (1) 280 (99) 3 (4) 81 (96)
Crude agreement (%)b 78 76
Percentage repigmentationc
0–25 109 (79) 29 (21)
25–50 90 (44) 116 (56)
50–75 58 (17) 283 (83)
> 75 33 (6) 499 (94)
Crude agreement (%)b 62d
Data are n (%) unless otherwise indicated. aTreatment success for VNS ≥ 4. bCrude agreement: figures in bold represent agreement between
VNS or percentage repigmentation as binary variables and global treatment success. Estimate of crude agreement for patient-reported VNS:
(103 + 532 + 342 + 1552 + 280)/3613 = 78%. cTreatment success for percentage repigmentation > 75%. dAgreement within percentage
repigmentation scale among clinicians: j = 026.
© 2015 The Authors. British Journal of Dermatology
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Table 4 Logistic regression of predictors of treatment success on the Vitiligo Noticeability Scale (VNS)
Variable n Unadjusted OR 95% CI P-value Adjusted OR 95% CI P-value
Logistic regression of patient-rated VNS success on image characteristics
Site
Face 27 – – – –
Hands 12 077 018–334 072 077 026–228 063
Sex
Female 14 – – – –
Male 13 188 047–746 154 083–285
Unknown 12 104 020–547 061 –a – 017
Pattern
Marginal 14 – – – –
Perifollicular 13 107 022–513 073 031–171
Diffuse 10 401 088–1827 176 067–459
Mixed 1 012 003–046 025 013–050
Complete 1 886 234–3356 < 001 485 126–1868 < 001
Hyperpigmentation
No 33 – – – –
Yes 6 040 009–169 021 010 006–018 < 010
Percentage repigmentationb 39 108 105–110 < 001 108 106–110 < 001
Logistic regression of patient-rated VNS success on patients’ characteristics
Response on behalf of
Self 93 – – – –
Other 8 117 076–179 047 104 055–198 090
Sex
Male 35 – – – –
Female 65 083 060–115 028 090 065–124 052
Age (years)
< 16 10 – – – –
17–30 14 139 091–214 203 130–317
31–45 24 101 065–157 130 084–201
46–65 36 081 050–132 121 077–190
> 65 15 086 056–133 007 144 093–222 003
Duration of vitiligo (years)
< 2 61 – – – –
2–5 11 067 036–122 060 027–131
5–10 13 053 031–092 058 027–123
> 10 71 057 036–092 010 054 025–114 044
Percentage skin affected
< 10 24 – – – –
10–25 38 083 056–124 081 056–117
25–50 17 084 054–130 089 054–147
50–80 15 084 048–144 086 052–142
80 7 066 035–122 073 065 035–120 062
Ethnicity
White 81 – – – –
Other 30 116 077–174 048 067 037–121 019
Country of residence
U.K. 79 – – – –
Other 22 155 109–218 001 181 094–349 008
Logistic regression of clinician-rated VNS success on clinicians’ characteristics
Sex
Male 17 – – – –
Female 16 094 066–133 072 100 073–136 100
Age (years)
≤ 45 12 – – – –
> 45 21 145 106–196 002 144 105–197 002
Ethnicity
White 16 – – – –
Other 17 083 059–118 030 092 068–124 057
(continued)
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different from that of the surrounding skin and this will not
be captured by the ‘100% repigmentation’ outcome. By focus-
ing on how noticeable the patch is after treatment, the VNS
allows factors such as colour match and pattern of repigmen-
tation to be taken into account when assessing treatment suc-
cess.
It should be noted that the VNS has primarily been devel-
oped as a way of assessing treatment response at the end of a
period of treatment. It is likely that VNS scores will initially
worsen during treatment, as the pigment may return in a dar-
ker shade than normal skin (hyperpigmentation). This effect is
often temporary, and so it may be preferable to assess VNS
scores at a time point after the end of treatment, once residual
hyperpigmentation has resolved. The optimal timing for
assessing the VNS after treatment will be addressed by further
validation work. Nevertheless, having a simple tool that allows
quantification of the degree of noticeability during treatment
can also help patients to reach informed decisions when
choosing between treatment options.
This study is the first to validate an outcome measure
assessing treatment success from the patient’s perspective. The
sample size of > 100 patients provided reasonable precision
for estimates of agreement with other measures of treatment
success, and specific hypotheses and criteria for success were
specified prior to data analysis.11 We also used the COSMIN
checklist to confirm that our study met the COSMIN reporting
requirements for validation studies, both for hypothesis testing
and interpretability.15 Our work reports the percentage of
missing items, gives a description of how missing items were
handled, calculated a sample size, formulated a priori hypothe-
ses, gave the expected direction and magnitude of correla-
tions, gave an adequate description of comparator instruments
and gave the distribution of total scores. Limitations of the
study (with respect to the COSMIN checklist criteria) were
that the sample size of clinicians was small, and the compara-
tor instruments (global treatment success and percentage of
repigmentation) have not been validated.
While it would be preferable to use actual photographs of
vitiligo pre- and post-treatment, limited access to such images
necessitated the use of software to simulate repigmentation.
Although images attempted to reproduce the patterns of repig-
mentation typical of those seen after treatment, they were
nonetheless simulations. However, this did allow us to control
the levels of repigmentation depicted (from fairly minimal to
full repigmentation), and ensure complete coverage of the
types of repigmentation patterns encountered in a clinical set-
ting. Nonetheless, further validation of the VNS is required,
using genuine clinical pre- and post-treatment images.
We focused on ‘high-expression’ sites (face and hands), as
these are areas where vitiligo has the greatest impact.16 This
means that our findings cannot necessarily be applied to viti-
ligo affecting other anatomical sites. Similarly, the images used
in the survey were all of adults with vitiligo, and although
some responses were made by the parents/guardians of chil-
dren with vitiligo, the numbers were so small that we cannot
draw firm conclusions about the validity of the outcome mea-
sure for assessing treatment response in children. The number
of clinician respondents was also relatively small, and may not
have been fully representative of all clinicians treating patients
with vitiligo. Another limitation of the study is that the partic-
ipants did not assess their own vitiligo patches. In order to
assess the validity of a patient-reported outcome, patients
should ideally use the tool on themselves, comparing pretreat-
ment images with the post-treatment clinical appearance; this
will be the focus of future work to further validate the scale.
The VNS does not include assessment of physical symptoms
such as itch, which can occasionally occur in vitiligo patches.
Although these symptoms are not unimportant, the main
impact of vitiligo is its visual appearance, so we have not
sought to incorporate any physical symptom components into
the scale.
Finally, it is possible that the cohort of patient questionnaire
respondents is not representative of all individuals who have
vitiligo. We used online methods to gather data, and provided
the questionnaire only in English. This may have excluded
potential respondents from certain ethnic and socioeconomic
backgrounds.
This study confirms that the VNS is a valid patient-reported
measure of vitiligo treatment success. The VNS is quick and
simple to complete, free to use and readily interpreted. How-
ever, further validation of the VNS is required, using larger
datasets, with genuine clinical pre- and post-treatment images,
covering a wider range of anatomical sites and ages of
patients, and with patients assessing only their own vitiligo
patches, both immediately after treatment and at time intervals
after treatment has been completed.
Table 4 (continued)
Variable n Unadjusted OR 95% CI P-value Adjusted OR 95% CI P-value
Country of residence
U.K. 14 – – – –
Other 19 095 065–137 077 064 032–127 020
Expert
No 24 – – – –
Yes 9 087 063–119 038 058 030–114 011
OR, odds ratio; CI, confidence interval. aNot estimated due to collinearity with site = hands. bOR is for every 10% increase in repigmenta-
tion.
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In future clinical trials, patient-reported VNS scores could
be used alongside objective outcome measures (such as per-
centage repigmentation), in order to capture patients’ views
and to aid interpretation of objective outcome measures. It
may also prove to be a useful tool for documentation of treat-
ment response in clinical records.
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